GLP-1 Receptor Agonists and PCOS Fertility: A 15–20 Minute Presentation

Slide 1: Opening Statement

Current evidence does not support using GLP-1 receptor agonists specifically to improve fertility outcomes in women with PCOS, because the only randomized trial showed no difference in live-birth rates—the outcome that matters most to patients. 1

Slide 2: The Evidence Gap

Quality of Current Data

The International Evidence-based Guideline (2023) rated fertility data from GLP-1 RA trials as low to very low certainty, reflecting small sample sizes, single-study evidence, and methodological limitations. 1
Only one randomized trial compared pre-gestational exenatide with metformin in PCOS women attempting conception. 1
This trial reported higher pregnancy rates with exenatide but no difference in live-birth rates—the gold-standard fertility endpoint. 1

Why This Matters

Live-birth rate is the outcome most relevant to patients, not pregnancy rate alone. 1
The lack of live-birth benefit means we cannot recommend GLP-1 RAs for fertility enhancement in PCOS. 1

Slide 3: First-Line PCOS Fertility Management

Established Recommendations

The American College of Obstetricians and Gynecologists recommends beginning with weight control and regular exercise as the foundation of fertility treatment in all PCOS patients attempting to conceive. 1
Weight loss of just 5% of initial body weight significantly improves both ovulation and pregnancy rates. 2, 1

Pharmacological First-Line

Clomiphene citrate remains the first-line pharmacological treatment for ovulation induction, effective in inducing ovulation in approximately 80% of PCOS patients, with 50% of those who ovulate conceiving. 1
Metformin improves ovulation frequency and appears safe during pregnancy, though effects on early pregnancy outcomes are not fully established. 1

Slide 4: Agent-Specific GLP-1 RA Data

Exenatide (Twice-Daily)

Did not demonstrate significant advantages over metformin for any measured outcome including ovulation, pregnancy, or live-birth. 1
Patients receiving exenatide experienced more adverse events than those on metformin. 1
Weight change was modest: gain of 0.3 kg to loss of 2.96 kg. 1
Bottom line: Exenatide should not be used for PCOS fertility management. 1

Liraglutide

Produced weight reductions of 0.3 kg to 3.38 kg compared with placebo. 1
Showed greater clinical impact on metabolic outcomes than exenatide. 1
Critical limitation: Most studies used sub-therapeutic doses (< 3 mg), below the dose known to optimize weight loss. 1, 3
No fertility-specific outcome data available. 1

Semaglutide

Achieved the largest weight loss among GLP-1 RAs: 3.47 kg to 6.5 kg in PCOS cohorts. 1
Evidence comes from a single small pilot study, providing insufficient data for fertility-outcome recommendations. 1, 3

Slide 5: The Weight-Loss and Fertility Connection

Theoretical Rationale

In PCOS, clinical outcomes correlate with the magnitude of weight loss; greater weight reduction is associated with improved ovulation and pregnancy metrics. 1
This relationship underpins the theoretical rationale for using GLP-1 RAs to enhance fertility. 1

The Problem

While GLP-1 RAs produce weight loss, this has not translated into improved live-birth rates in the available trial data. 1
Weight loss alone is insufficient if it doesn't result in successful pregnancies and live births. 1

Slide 6: Comparative Efficacy Meta-Analysis

GLP-1 RAs vs. Metformin

A 2021 meta-analysis of 7 RCTs (464 overweight/obese PCOS women) found GLP-1 RAs showed better effects than metformin on:
- BMI reduction (mean difference -1.72; 95% CI -2.46 to -0.99, P < .001) 4
- Insulin resistance improvement (HOMA-IR: SMD -0.37; 95% CI -0.60 to -0.15, P = .001) 4
- Lower abdominal girth 4

Critical Caveat

This evidence was rated as low quality. 4
The combination of GLP-1 RA plus metformin exhibited similar effects to GLP-1 RA alone, offering no additional benefit. 4
Gastrointestinal discomfort was similar between groups. 4

Slide 7: Safety Profile

Adverse Events

Across trials, GLP-1 RAs produced more adverse events than control treatments, including metformin. 1, 5, 3
Gastrointestinal symptoms (nausea, vomiting, diarrhea) are the most common. 5, 3

Specific Safety Concerns

Use caution in patients with history of pancreatitis, as acute pancreatitis is a rare but documented adverse effect. 1, 3
Avoid in patients with gastroparesis and consider dose reduction if symptomatic gastrointestinal side effects occur. 1, 3

Longer-Acting Agents

Longer-acting GLP-1 RA medications (liraglutide, semaglutide) have advantages with improved adherence, glycemic effects, and tolerance compared to shorter-acting options like exenatide. 5, 3

Slide 8: When GLP-1 RAs May Be Considered

Metabolic Management Before Conception

For women with PCOS and obesity (BMI ≥ 30 kg/m²) who prioritize metabolic health before conception, structured lifestyle modification is recommended first. 1
Target: 500–750 kcal/day reduction plus resistance training to preserve lean body mass. 1

Off-Label Use Context

In this metabolic optimization context, liraglutide or semaglutide (but not exenatide) may be considered for additional weight reduction. 1
Mandatory requirements:
- Effective contraception must be used during treatment. 1
- A wash-out period must be planned before attempting pregnancy. 1
GLP-1 RAs are not FDA-approved for PCOS treatment or fertility enhancement. 1, 3

Slide 9: Guideline Recommendations

2023 International Evidence-Based Guideline

Anti-obesity medications, including GLP-1 RAs, could be considered for weight management in adult women with PCOS and BMI ≥30 kg/m², in addition to active lifestyle intervention. 1, 3
This recommendation follows general population obesity guidelines, not PCOS-specific fertility data. 3

First-Line Treatments Remain Unchanged

For women not attempting to conceive: combined oral contraceptives. 5, 3
For women attempting to conceive: lifestyle modification plus clomiphene citrate. 1

Slide 10: Lifestyle Management as Foundation

Evidence-Based Lifestyle Approach

The 2020 International Evidence-based Guideline emphasizes multicomponent lifestyle intervention including diet, exercise, and behavioral strategies as central to PCOS management. 2
Focus on weight and healthy lifestyle behaviors, with weight gain prevention. 2
No specific diet is recommended over others. 2

Exercise Benefits

Exercise programs show positive effects even without weight loss in PCOS patients. 1
When used with lifestyle interventions, liraglutide helps preserve lean body mass compared to liraglutide alone, suggesting physical activity should accompany treatment. 5, 3

Slide 11: Study Limitations

Methodological Flaws

Most studies used suboptimal medication doses (e.g., liraglutide < 3 mg). 1, 3
Many studies used short 12-week protocols, limiting the ability to demonstrate changes in important clinical outcomes like hirsutism and fertility. 3
Quality trials are woefully inadequate given the prevalence and impact of PCOS. 5, 3

Research Gaps

There is a significant research gap regarding GLP-1 RA use specifically in non-obese PCOS patients. 5
The 2023 International Evidence-based Guideline identifies the role of anti-obesity agents in PCOS management as a high priority for future research. 3

Slide 12: Pregnancy Planning Considerations

Shared Decision-Making

Engage in shared decision-making with PCOS patients, considering both potential benefits and adverse events of GLP-1 RAs. 1, 3

Monitoring Once Conception Occurs

Monitor PCOS patients closely throughout pregnancy: blood pressure, kidney function, and proteinuria. 1
Prescribe low-dose aspirin from week 12 to week 36 to reduce preeclampsia risk. 1

Contraception During Treatment

If using GLP-1 RAs for metabolic optimization, effective contraception is mandatory until a wash-out period is completed. 1

Slide 13: Mechanistic Insights

Beyond Weight Loss

GLP-1 seems to have anti-inflammatory and anti-fibrotic effects in the gonads and endometrium affected by obesity, diabetes, and PCOS. 6
GLP-1 RAs and DPP-4 inhibitors can reverse polycystic ovary morphology in preclinical models. 6
They decrease serum concentrations of androgens and their bioavailability in women with PCOS. 6

Reproductive System Distribution

The anatomical distribution of GLP-1 receptor throughout the reproductive system indicates GLP-1 might be an important modulating signal connecting the reproductive and metabolic system. 6

Clinical Translation Gap

Despite promising mechanistic data, these effects have not translated into improved live-birth rates in clinical trials. 1

Slide 14: Metabolic vs. Reproductive Outcomes

Where GLP-1 RAs Excel

Metabolic improvements: insulin resistance, weight loss, abdominal fat reduction. 1, 4, 7
Hormonal improvements: free testosterone and SHBG levels in some studies. 8
Menstrual regularity: increased menstrual frequency reported. 8, 6

Where Evidence Falls Short

Fertility outcomes: no demonstrated benefit for live-birth rates. 1
Reproductive endpoints: insufficient data on ovulation rates, pregnancy rates, and pregnancy complications. 3

The Disconnect

Improvements in metabolic and hormonal parameters do not automatically translate to improved fertility outcomes. 1

Slide 15: Clinical Algorithm

Step 1: All PCOS Patients Attempting Conception

Initiate lifestyle modification: 500–750 kcal/day reduction plus resistance training. 1
Target 5% weight loss if overweight/obese. 2, 1

Step 2: Pharmacological Ovulation Induction

First-line: Clomiphene citrate. 1
Consider metformin for insulin resistance. 1

Step 3: GLP-1 RA Consideration (Off-Label)

Only if: BMI ≥30 kg/m² AND patient prioritizes metabolic optimization before conception. 1
Agent selection: Liraglutide or semaglutide (NOT exenatide). 1
Requirements: Effective contraception + planned wash-out period. 1
Goal: Metabolic health improvement, NOT fertility enhancement. 1

Step 4: Fertility Treatment

After metabolic optimization and GLP-1 RA discontinuation, proceed with standard fertility treatments. 1

Slide 16: What NOT to Do

Avoid These Pitfalls

Do NOT use GLP-1 RAs as first-line fertility treatment in PCOS. 1
Do NOT use exenatide for PCOS management—it offers no benefit over metformin with more adverse events. 1
Do NOT prescribe GLP-1 RAs during active conception attempts without a wash-out period. 1
Do NOT use subtherapeutic doses (e.g., liraglutide < 3 mg) and expect optimal results. 1, 3
Do NOT rely on pregnancy rates alone—live-birth rate is the outcome that matters. 1

Slide 17: Future Research Needs

Urgent Priorities

High-quality, multicenter studies of newer GLP-1 RAs, particularly semaglutide, in PCOS are urgently needed. 5, 3
Studies must incorporate reproductive, metabolic, and psychological outcomes. 3
Live-birth rate must be the primary fertility endpoint. 1

Study Design Requirements

Adequate sample sizes and longer duration (> 12 weeks). 3, 8
Optimal medication doses (e.g., liraglutide 3 mg, semaglutide 2.4 mg). 1, 3
Prolonged post-interventional monitoring. 8
Head-to-head comparisons between different GLP-1 RAs. 3

Slide 18: Special Populations

Non-Obese PCOS Patients

There is insufficient evidence to recommend GLP-1 RAs as first-line therapy in non-obese PCOS patients. 5
Current evidence is primarily based on studies in obese patients. 5
If considering GLP-1 RAs in non-obese PCOS patients with metabolic abnormalities, liraglutide or semaglutide would be preferred over exenatide. 5

Patients with Concurrent Conditions

Patients with concurrent insulin resistance or prediabetes may benefit from GLP-1 RA use for metabolic management. 3
In non-diabetic patients, GLP-1 RAs produce greater weight loss (6.1–17.4%) compared to patients with diabetes (4–6.2%). 5

Slide 19: Cost-Effectiveness Considerations

Economic Factors

GLP-1 RAs are expensive medications. 4
Cost-effectiveness analyses are warranted to guide GLP-1 RA use in PCOS treatment. 4
Given the lack of fertility benefit, using GLP-1 RAs specifically for fertility enhancement is not cost-effective. 1

Resource Allocation

Resources may be better allocated to proven fertility treatments (clomiphene citrate, metformin) and lifestyle interventions. 2, 1

Slide 20: Take-Home Messages

Key Points for Clinical Practice

GLP-1 RAs are NOT recommended for fertility enhancement in PCOS because they do not improve live-birth rates. 1
First-line fertility management remains lifestyle modification plus clomiphene citrate. 2, 1
If using GLP-1 RAs, the indication is metabolic optimization (BMI ≥30 kg/m²), NOT fertility improvement. 1
Liraglutide or semaglutide are preferred over exenatide if GLP-1 RA use is considered. 1
Effective contraception and wash-out period are mandatory if using GLP-1 RAs before conception attempts. 1
The evidence base is low to very low quality—more research is urgently needed. 1, 3

Can you prepare a 15‑20‑minute slide presentation summarizing recent evidence on glucagon‑like peptide‑1 receptor agonists (e.g., liraglutide, semaglutide) as a therapeutic option to improve fertility in overweight or obese women aged 18‑35 with polycystic ovary syndrome?

Help us tailor your experience